Halozyme Therapeutics (HALO) Prepaid Assets (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Prepaid Assets of $121.9 million for Q1 2026, up 21.6% year-over-year from $100.2 million in Q1 2025, and up 88.54% quarter-over-quarter from $64.6 million in Q4 2025.
Halozyme Therapeutics (HALO) Prepaid Assets (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Prepaid Assets for 17 consecutive years, with $121.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets rose 21.6% year-over-year to $121.9 million; the TTM figure through Mar 2026 stood at $121.9 million (up 21.6% YoY), while the FY2025 annual figure was $64.6 million, up 65.95% from the prior year.
- Prepaid Assets advanced to $121.9 million in Q1 2026 per HALO's latest filing, from $64.6 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $150.7 million in Q3 2025 and bottomed at $37.0 million in Q1 2023.
- Historically, Prepaid Assets has averaged $73.6 million across 5 years, with a median of $63.1 million in 2022.
- Annual changes were most pronounced in 2023 — Prepaid Assets plunged 41.32% — and 2024, when it soared 149.94%.
- Halozyme Therapeutics' Prepaid Assets stood at $71.3 million in 2022, then slumped by 31.84% to $48.6 million in 2023, then fell by 19.88% to $39.0 million in 2024, then surged by 65.95% to $64.6 million in 2025, then jumped by 88.54% to $121.9 million in 2026.
- Business Quant data shows HALO's Prepaid Assets at $121.9 million in Q1 2026, $64.6 million in Q4 2025, and $150.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 164.15 Mn |
| Mar 31, 2026 | 121.87 Mn |
| Dec 31, 2025 | 64.64 Mn |
| Sep 30, 2025 | 150.65 Mn |
| Jun 30, 2025 | 76.65 Mn |
| Mar 31, 2025 | 100.23 Mn |
| Dec 31, 2024 | 38.95 Mn |
| Sep 30, 2024 | 123.67 Mn |
| Jun 30, 2024 | 106.17 Mn |
| Mar 31, 2024 | 45.69 Mn |
| Dec 31, 2023 | 48.61 Mn |
| Sep 30, 2023 | 49.48 Mn |
| Jun 30, 2023 | 57.29 Mn |
| Mar 31, 2023 | 37.01 Mn |
| Dec 31, 2022 | 71.33 Mn |
| Sep 30, 2022 | 51.04 Mn |
| Jun 30, 2022 | 45.60 Mn |
| Mar 31, 2022 | 63.06 Mn |
| Dec 31, 2021 | 40.48 Mn |
| Sep 30, 2021 | 33.30 Mn |